Antiglaucoma drug which acts by increasing uveo- sclerol outflow –
💡 Explanation
**Core Concept**
The question requires knowledge of antiglaucoma medications and their mechanisms of action, specifically those that increase uveoscleral outflow. Uveoscleral outflow is one of the two main pathways for aqueous humor drainage in the eye, the other being trabecular meshwork outflow.
**Why the Correct Answer is Right**
The correct answer is a medication that increases the outflow of aqueous humor through the uveoscleral pathway. This is achieved by increasing the permeability of the ciliary epithelium, allowing more aqueous humor to seep through and escape from the eye. This mechanism is particularly useful in glaucoma treatment, as it can reduce intraocular pressure (IOP) without affecting the trabecular meshwork.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is likely a medication that acts on the trabecular meshwork, such as a beta-blocker or a carbonic anhydrase inhibitor. These medications do not increase uveoscleral outflow.
* **Option B:** This option may be a medication that is used to treat glaucoma, but it does not act by increasing uveoscleral outflow. For example, prostaglandin analogs work by increasing trabecular meshwork outflow, not uveoscleral outflow.
* **Option D:** This option is likely a medication that is used to treat other conditions, such as allergic reactions or pain. It does not have a role in glaucoma treatment or uveoscleral outflow.
**Clinical Pearl / High-Yield Fact**
It's essential to remember that different antiglaucoma medications have distinct mechanisms of action, and choosing the right medication depends on the underlying cause of glaucoma and the patient's individual characteristics.